The United States healthcare system was not designed with Black/African American patients in mind, nor has it adapted to serve the unique health-related social needs of Black people. Historic and modern racist practices, from discriminatory laws and policies to lack …
The Centers for Medicare & Medicaid Services (CMS) defines health-related social needs (HRSN) as unmet, adverse social and economic conditions that contribute to a patient’s poor health and affect their ability to maintain well-being. Unemployment, food insecurity, and lack of …
The Agency for Healthcare Research and Quality (AHRQ) administers the Consumer Assessment of Healthcare Providers and Systems (CAHPS) program, which creates surveys to evaluate patients’ experiences with ambulatory and facility-level care in commercial and Medicaid plans. The Healthcare Effectiveness Data …
Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefits provide comprehensive and preventive health care services for children under age 21 who are enrolled in Medicaid. Federal statutes and regulations require that EPSDT preventative, dental, mental, developmental, and specialty services …
According to the NIH, an estimated 21 million adults experienced at least one major depressive episode in 2020. Clinicians understand that female gender, social isolation, and disturbed family environment increase risk, but may not recognize presenting symptoms of depression in …
Clinicians face considerable hurdles when diagnosing and managing narcolepsy and idiopathic hypersomnia (IH), largely due to overlapping symptoms, insufficient formal training in sleep medicine, and limited recognition of associated psychiatric and cardiometabolic comorbidities. Compounding the challenge, some therapeutic agents—most notably …
Metabolic dysfunction-associated steatohepatitis (MASH) is a growing clinical challenge due to its increasing prevalence, complex pathophysiology, and strong association with comorbid conditions such as cardiovascular disease and obesity. Evolving diagnostic criteria, risk stratification tools, and new therapeutic options require health …
GLP-1 receptor agonists (GLP-1 RAs) are a top-tier recommendation for patients with type 2 diabetes (T2D), especially those with concomitant cardiovascular disease (CVD), chronic kidney disease (CKD), or obesity. Backed by robust clinical trial data and endorsed across leading guidelines, …
